Gentium to present three abstracts on Defibrotide at American Society of Hematology

Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that three abstracts on Defibrotide will be presented at the 52^nd Annual Meeting and Exposition of the American Society of Hematology to be held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

Poster session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Poster II, Hall A3/A4, Monday, December 6, 2010, 6:00 PM - 8:00 PM

"Meta-analysis of Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with comparison to a Historical Control (HC)" (Poster Board III-260). P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA.

"Safety of Defibrotide (DF) in Stem Cell Transplant (SCT) patients (Pts)" (Poster Board III-261). S. Corbacioglu et al., University of Regensburg, Regensburg, Germany.

Oral session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Transplant Related Toxicities, Room 110A, Tuesday, December 7, 2010, 8:45 AM

"Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): results of a treatment IND expanded access protocol" (Abstract #906), P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA.

For more details on the congress, please visit the official congress web site:

http://www.hematology.org/Meetings/Annual-Meeting/